Beta Bionics, Inc. (NASDAQ:BBNX) Short Interest Update

Key Points

• Short interest jumped 24.5% in March to 7,005,310 shares (15.8% of shares sold short), representing a short-interest ratio of about 6.3 days based on average daily volume.
• Insiders sold stock (34,705 shares worth ~$945,653 last quarter, including sales by Mike Mensinger and CFO Stephen Feider) even as major institutions increased positions — notably Vanguard added ~1.51 million shares (a 213.5% increase) and other large funds boosted stakes.
• Analyst/stock backdrop: the consensus is a "Moderate Buy" with an average target of $23.20, while the stock trades at $10.76, shows negative EPS/margins, and a high beta indicating elevated volatility.

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) saw a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 7,005,310 shares, a growth of 24.5% from the February 26th total of 5,626,149 shares. Based on an average daily volume of 1,104,702 shares, the short-interest ratio is presently 6.3 days. Currently, 15.8% of the company's stock are sold short.

Insider Transactions at Beta Bionics

In other Beta Bionics news, insider Mike Mensinger sold 7,800 shares of the stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $29.61, for a total transaction of $230,958.00. Following the completion of the sale, the insider directly owned 82,952 shares of the company's stock, valued at approximately $2,456,208.72. This represents a 8.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Stephen Feider sold 20,000 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total value of $590,600.00. Following the sale, the chief financial officer owned 42,614 shares of the company's stock, valued at approximately $1,258,391.42. This represents a 31.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 34,705 shares of company stock valued at $945,653 over the last quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Eventide Asset Management LLC increased its stake in Beta Bionics by 0.8% during the 4th quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company's stock worth $152,233,000 after buying an additional 37,476 shares during the period. Farallon Capital Management LLC grew its stake in shares of Beta Bionics by 2.6% in the third quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company's stock worth $85,718,000 after acquiring an additional 110,000 shares in the last quarter. Soleus Capital Management L.P. increased its position in shares of Beta Bionics by 12.5% during the second quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company's stock worth $55,622,000 after acquiring an additional 424,817 shares during the period. Sands Capital Alternatives LLC raised its stake in shares of Beta Bionics by 15.0% in the second quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company's stock valued at $51,981,000 after acquiring an additional 466,331 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Beta Bionics by 213.5% in the third quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company's stock valued at $44,036,000 after acquiring an additional 1,509,217 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Truist Financial decreased their price objective on shares of Beta Bionics from $37.00 to $25.00 and set a "buy" rating for the company in a research report on Monday, February 2nd. Stifel Nicolaus decreased their target price on Beta Bionics from $25.00 to $22.00 and set a "buy" rating on the stock in a research report on Wednesday, February 18th. The Goldman Sachs Group reissued a "buy" rating and issued a $25.00 price target on shares of Beta Bionics in a report on Thursday, January 15th. Bank of America cut shares of Beta Bionics from a "buy" rating to a "neutral" rating in a research report on Friday, January 9th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Beta Bionics in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $23.20.

Beta Bionics Stock Performance

Shares of BBNX stock opened at $10.76 on Monday. The company's 50-day moving average price is $13.06 and its 200-day moving average price is $21.37. Beta Bionics has a twelve month low of $8.89 and a twelve month high of $32.71. The stock has a market cap of $477.53 million, a price-to-earnings ratio of -5.52 and a beta of 5.59.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.12. The business had revenue of $32.12 million during the quarter. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.